GBECAM 0115 – AMAZONA III | Prospective evaluation of breast cancer at Brazilian institutions – Project AMAZONA III
LACOG 0221 – BRAVE | Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil (LACOG 0221) – BRAVE Study
LACOG 0413 – Male Breast Cancer | Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study.
LACOG 0419 – NEOSAMBA | Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer OPEN FOR RECRUITMENT
LACOG 0615 – LATINABreast | A study to observe patients characteristics, treatment patterns and outcomes in patients with newly diagnosed breast cancer in Latin America.
LACOG 0721 – Cherry Pick | Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients with HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade – CHERRY-PICK TRIAL (LACOG 0721)
LACOG 0111 – MGH | MGH – International Breast Cancer Collaborative Project: Determination of an Endocrine Responsive Metastatic Breast Cancer Signature.
LACOG 0115 – LORELEI | A Phase II Randomized, Double-Blind, Parallel Cohort Study of Neoadjuvant Letrozole + GDC-0032 versus Letrozole + Placebo in Post-Menopausal Women with ER+/HER2- Primary Breast Cancer.
LACOG 0312 – METASTATIC BC | Metastatic breast cancer in Brazil: characterization of patients and treatments.
LACOG 0414 | Evaluation of the attitude of premenopausal patients with breast cancer to the risk of loss of fertility caused by chemotherapy.
LACOG 0715 – PALLAS | A randomized phase III trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast Cancer
LACOG 0801 – GLICO | A randomized open-label, phase II study of lapatinib/capecitabine or lapatinib/vinorelbine or lapatinib/gemcitabine in subjects with Her2/neu amplified metastatic breast cancer patients progressing after taxanes treatment.
LACOG 2118 – ALEXANDRA/IMpassion 030 | A phase III, multicenter, randomized, open-label study comparing Atezolizumab (ANTI-PD-L1 ANTIBODY) in combination with adjuvant Anthracycline/Taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer.
LACOG 0119 | Multicenter retrospective database on prognostic and predictive factors in patients with neuroendocrine tumor
LACOG 0222 – GASPAR | Epidemiological characteristics of gastric and pancreatic cancers in Latin America OPEN FOR RECRUITMENT
LACOG 0421 – ACTION HIV | ACTION HIV (Anal Cancer TherapIes and Outcomes iNitiative for patients living with and without HIV): A global record of patients with anal squamous cell carcinoma with and without HIV infection. OPEN FOR RECRUITMENT
LACOG/GTG 1318 – ANAL REGISTRY | A multicenter retrospective database on prognostic and predictive factors in patients with squamous cell carcinoma of the anus.
LACOG 0121 – PET-PSMA | Retrospective analysis of 68Ga-PSMA-PET in patients with prostate cancer: experience from Brazil (LACOG pPR015)
LACOG 0217 – IRONMAN | Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer
LACOG 0218 – Hercules | A phase II trial of pembrolizumab combined with cisplatin-based chemotherapy as first-line systemic therapy in advanced penile cancer
LACOG 0519 – PEACE III | A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III
LACOG 0522 – DORA | DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC). OPEN FOR RECRUITMENT
LACOG 0620 – ExBAT | Extreme Bipolar Androgen Therapy with Darolutamide and Testosterone Cypionate in Patients with Metastatic Castration-Resistant Prostate Cancer (ExBAT trial)
LACOG 1120 – RENAL REGISTRY | Clinicopathological characteristics and outcomes of patients with Renal Cell Carcinoma in Latin America
LACOG 1818 – Prostate Cancer Registry | Survival outcomes in metastatic prostate cancer in the Brazilian population – analysis of individual characteristics and treatment modalities in different national health institutions
LACOG 2018 – Foundation Penile | Molecular characterization of penile cancer in developing countries.
LACOG 0415 – APA in Prostate Cancer | Phase II randomized study of Abiraterone acetate plus ADT versus APALUTAMIDE versus Abiraterone and APALUTAMIDE in patients with advanced prostate cancer with non-castrate testosterone levels
LACOG 0515 -Testicular | Registry Multicentric database of patients with germ cell tumor with the purpose of clinical and pathological characterization and evaluation of cancer treatment outcomes
LACOG 1518 – Bladder Cancer Registry | Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America: Retrospective and Translational Multicenter Database
LACOG 0223 / GOG-3073 – ROSELLA | A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian Primary Peritoneal, or Fallopian-Tube Cancer
LACOG 0521 – MADONNA | Molecular and epidemiological characteristics of endometrial cancer in Brazil OPEN FOR RECRUITMENT
LACOG 0623 – eVOLVE-Cervical | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical) OPEN FOR RECRUITMENT
LACOG 0820 – EVITA LATAM | Epidemiological Landscape of Cervical Cancer in Latin America
LACOG 0920 – Senticol III | International Validation Study Of Sentinel Node Biopsy In Early Cervical Cancer
LACOG 1018 – PALBO in Ovarian Cancer | Palbociclib plus letrozole combination after progression to second line chemotherapy for women with ER/PR-positive ovarian cancer
LACOG 1220 – CONOR | CONOR: A Collaborative trial of Niraparib to evaluate patients with Ovarian cancer in the expanded access program in Latin America
LACOG 0215 – EVITA | Prospective evaluation of patients with uterine cervical cancer in Brazilian health institutions
LACOG 0319 | Quality Of Life Assessment Study In Patients With Metastatic Head And Neck Neoplasia Submitted To Immunotherapy In Brazil
LACOG 0720 – SMART-KEY | SMART-KEY: A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers
LACOG 0318 – Induction | Randomized, Open-label, Phase III Trial of Induction Chemotherapy Followed by Chemoradiotherapy versus Upfront Chemoradiotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma
LACOG 0116 – LATINO LUNG | Prospective epidemiological study of metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America
LACOG 0118 – RELANCE | Retrospective epidemiological study of Locally Advanced Non Small Cell Lung Cancer
LACOG 0120 – EAP durva lung cancer | Durvalumab as maintenance in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real World Data from an Expanded Access Program in Brazil.
LACOG 0322 – EDUR-BRA | A Real-World Assessment of the demographic, clinical characteristics and outcomes of a Brazilian cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer receiving Durvalumab combined with Platinum-Etoposide in (ES-SCLC) in Brazil. OPEN FOR RECRUITMENT
LACOG 0821 – AMIGO-1 | A single arm, phase 2 study of amivantamab, lazertinib and pemetrexed for first-line treatment of recurrent / metastatic non-small cell lung cancers (NSCLCs) with EGFR mutations OPEN FOR RECRUITMENT
LACOG 1918 | Patient Journey with advanced lung cancer positive for ALK fusion in Brazil
LACOG 2218 – PACIFIC BRAZIL | Intensified chemo-immuno-radiotherapy with durvalumab (MEDI4736) for stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II study (PACIFIC BRAZIL)
LACOG 0211 – ALK | A clinical and epidemiologic study of EML4-ALK and other ALK fusions genes in lung cancer patients in Latin American.
LACOG 0417 – CNS MTX | Retrospective Analysis of Patients with Non-Small Cell Lung Cancer with Brain Metastasis
LACOG 0618 | Safety and Efficacy of Nivolumab in previously treated patients with advanced NSCLC: Real World Data from an Expanded Access Program in Brazil
Parsimony | Non-small-cell lung cancer (NSCLC) stage III treated with concurrent chemoradiation followed or not by consolidation chemotherapy.
LACOG 0619 | Characterization of patients with diffuse gliomas in Brazil
LACOG 0122 – RADIANT | Extreme hypofractionation radiotherapy in patients with breast cancer in Brazil: retrospective cohort study OPEN FOR RECRUITMENT
LACOG 0213 – AUGMENT | A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/RefractoryIndolent Lymphoma.
LACOG 0214 – FINEP | Validation of 99mTc- EDDA – HYNIC -TOC kits for diagnosis of neuroendocrine tumors
